News for Immutep Limited (IMMP)

Immutep Limited (NASDAQ:IMMP) is one of the 7 Best ASX Stocks to Buy Now. On June 23, Immutep Limited (NASDAQ:IMMP) announced positive initial efficacy data and continued favourable safety data from the placebo-controlled, double-blind first-in-human Phase I study evaluating IMP761. This is the first-in-class LAG-3 agonist antibody for autoimmune diseases. The company stated that through the highest […]

**media[661880]**

**media[637926]**

Immutep Limited (IMMP) has reported promising outcomes from the INSIGHT-003 study, which is examining the effectiveness of eftilagimod alpha combined with KEYTR

The ASX200 is set to open lower today, following a mixed night for US stocks, driven by continuing trade uncertainty and inflation data

Immutep's eftilagimod shows a 17.6-month survival benefit in head and neck cancer. Find out how and why IMMP is continuing to develop in the right direction.

U.S. stock futures were lower this morning, with the Dow futures falling over 200 points on Tuesday. Shares of Ichor Holdings, Ltd. ICHR fell sharply in today'...

Key Highlights: Immutep Limited reports a remarkable median overall survival rate in a pivotal cancer trial. Stock analysts predict a strong upside poten

Immutep Limited initiates patient dosing in its TACTI-004 Phase III trial targeting advanced non-small cell lung cancer. Analysts set a promising one-ye

**media[614544]**

The ASX200 is set to perform strongly on Monday, after a session of rallies on Wall Street buoyed by optimistic jobs data

Media Release First patient safely dosed in TACTI-004 Phase III lung cancer trial, marking a significant milestonePivotal TACTI-004 trial design presented at t

Discover why Immutep's Eftilagimod Alpha shows promise in NSCLC and HNSCC trials, but cautious investment is advised. Explore more details here.

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with efti will enrol ap

**media[575885]**

Immutep Ltd has dosed the first patient of its Phase 3 TACTI-004 non-small cell lung cancer trial in its final stage of clinical study.

SYDNEY, AUSTRALIA, March 20, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; IMMP) (”œImmutep” or ”œthe Company”), a late-stage immunotherapy comp

**media[571871]**

We recently compiled a list of the 10 Best Long Term ASX Stocks to Buy Now. In this article, we are going to take a look at where Immutep Limited (NASDAQ:IMMP) stands against the other long term ASX ...